Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00460096 | Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency | PHASE2 | COMPLETED | 50 | — | — | Mar 1, 2007 | Sep 1, 2007 | Oct 17, 2007 | 3 | United States |
| Name | Type | Description |
|---|---|---|
| Kamada-API | DRUG | - |
Inclusion Criteria: 1. Signed informed consent. 2. "At-risk" alleles associated with serum AAT \< 11 μM including null alleles and deficiency alleles. This must be documented in the subject's history or laboratory tests performed at screening. 3. At least 18 years of age. 4. Evidence of lung diseas...